Efficacy and safety of camrelizumab-based comprehensive treatment for non-small cell lung cancer: a systematic review and meta-analysis.

ABSTRACT:

Background

Many studies show that camrelizumab combination therapy can significantly improve progression-free survival (PFS) and overall survival (OS) in non-small cell lung cancer (NSCLC). However, the time of camrelizumab to market is short, and there is no systematic evaluation of camrelizumab-based comprehensive treatment of NSCLC.

Objectives

To systematically evaluate the efficacy and safety of camrelizumab in comprehensively treating NSCLC.

Design

A systematic review and meta-analysis.

Data sources and methods

Databases, including PubMed, Web of Science, Embase, and Cochrane, were searched by computer before August 2023 based on Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, and reports on the efficacy and safety of

SUBMITTER: Maimaitiyiming N 

PROVIDER: S-EPMC11457245 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature